Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: Promising agents against multiple myeloma

Journal of Medicinal Chemistry

Volumn 56, Issue 18, 2013, Pages 7190-7200

  Page, Brent D G ^a   Croucher, Danielle C ^b   Li, Zhi Hua ^b   Haftchenary, Sina ^a   Jimenez Zepeda, Victor H ^b   Atkinson, Jennifer ^b   Spagnuolo, Paul A ^b   Wong, Yoong Lim ^a   Colaguori, Robert ^a   Lewis, Andrew M ^a   Schimmer, Aaron D ^b   Trudel, Suzanne ^b   Gunning, Patrick T ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN INHIBITOR; STAT3 PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING ASSAY; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE POLARIZATION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MOLECULAR DOCKING; MULTIPLE MYELOMA; PROTEIN PHOSPHORYLATION; TARGET CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR DOCKING SIMULATION; MULTIPLE MYELOMA; SRC HOMOLOGY DOMAINS; STAT3 TRANSCRIPTION FACTOR;

EID: 84884991112     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3017255     Document Type: Article

References (35)

1. Haftchenary, S.; Avadisian, M.; Gunning, P. T. Inhibiting aberrant Stat3 function with molecular therapeutics: A progress report Anticancer Drugs 2011, 22, 115-127
2. Page, B. D. G.; Ball, D. P.; Gunning, P. T. Signal transducer and activator of transcription 3 inhibitors: A patent review Expert Opin. Ther. Pat. 2011, 21, 65-83
3. Fletcher, S.; Turkson, J.; Gunning, P. T. Molecular approaches towards the inhibition of the Signal Transducer and Activator of Transcription 3 (Stat3) Protein ChemMedChem 2008, 3, 1159-1168
4. Fletcher, S.; Drewry, J. A.; Shahani, V. M.; Page, B. D. G.; Gunning, P. T. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein Biochem. Cell Biol. 2009, 87, 825-833
5. Bromberg, J. F.; Wrzeszczynska, M. H.; Devgan, G.; Zhao, Y.; Pestell, R. G.; Albanese, C.; Darnell, J. E., Jr. Stat3 as an oncogene Cell 1999, 98, 295-303 (Pubitemid 29380565)
6. Bowman, T.; Garcia, R.; Turkson, J.; Jove, R. STATs in oncogenesis Oncogene 2000, 19, 2474-2488 (Pubitemid 30339203)
7. Bromberg, J.; Darnell, J. E., Jr. The role of STATs in transcriptional control and their impact on cellular function Oncogene 2000, 19, 2468-2473 (Pubitemid 30339202)
8. Raab, M. S.; Podar, K.; Breitkreutz, I.; Richardson, P. G.; Anderson, K. C. Multiple myeloma Lancet 2009, 374, 324-339
9. Munshi, N. C. Plasma cell disorders: An historical perspective Hematology 2008, 297
10. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeldis, J.; Barlogie, B.; Siegel, D.; Crowley, J. Antitumor activity of thalidomide in refractory multiple myeloma N. Engl. J. Med. 1999, 341, 1565-1571
11. Badros, A.; Gahres, N. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: Add it up and wait Clinical Advances in Hematology and Oncology 2005, 3, 916-917 (Pubitemid 43168749)
12. Alas, S.; Bonavida, B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis Clin. Cancer Res. 2003, 9, 316-326 (Pubitemid 36109748)
13. Catlett-Falcone, R.; Landowski, T. H.; Oshiro, M. M.; Turkson, J.; Levitzki, A.; Savino, R.; Ciliberto, G.; Moscinski, L.; Fernández-Luna, J. L.; Nuñez, G.; Dalton, W. S.; Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells Immunity 1999, 10, 105-115 (Pubitemid 29077388)
14. Lin, L.; Benson, D. M., Jr.; Deangelis, S.; Bakan, C. E.; Li, P.; Li, C.; Lin, J. A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells Int. J. Cancer 2012, 130, 1459-1469
15. Fletcher, S.; Page, B. D. G.; Zhang, X.; Yue, P.; Li, Z. H.; Sharmeen, S.; Singh, J.; Zhao, W.; Schimmer, A. D.; Trudel, S.; Turkson, J.; Gunning, P. T. Antagonism of the Stat3-Stat3 Protein Dimer with Salicylic Acid-Based Small Molecules ChemMedChem 2011, 6, 1459-1470
16. Heim, M. H.; Kerr, I. M.; Stark, G. R.; Darnell, J. E., Jr. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway Science 1995, 267, 1347-1349
17. Gunning, P. T.; Glenn, M. P.; Siddiquee, K. A.; Katt, W. P.; Masson, E.; Sebti, S. M.; Turkson, J.; Hamilton, A. D. Targeting protein-protein interactions: Suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders ChemBioChem 2008, 9, 2800-2803
18. Becker, S.; Groner, B.; Müller, C. W. Three-dimensional structure of the Stat3β homodimer bound to DNA Nature 1998, 394, 145-151 (Pubitemid 28325960)
19. Siddiquee, K. A. Z.; Gunning, P. T.; Glen, M.; Katt, W. P.; Zhang, S.; Schroeck, C.; Sebti, S. M.; Jove, R.; Hamilton, A. D.; Turkson, J. An oxazole-based small-molecule stat3 inhibitor modulates stat3 stability and processing and induces antitumor cell effects ACS Chem. Biol. 2007, 2, 787-798 (Pubitemid 351166054)
20. Mandai, P. K.; Lião, W. S.; McMurray, J. S. Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3 Org. Lett. 2009, 11, 3394-3397
21. Coleman, D. R., IV; Ren, Z.; Mandal, P. K.; Cameron, A. G.; Dyer, G. A.; Muranjan, S.; Campbell, M.; Chen, X.; McMurray, J. S. Investigation of the binding determinants of phosphopeptides targeted to the Src homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor J. Med. Chem. 2005, 48, 6661-6670 (Pubitemid 41504722)
22. Shahani, V. M.; Yue, P.; Fletcher, S.; Sharmeen, S.; Sukhai, M. A.; Luu, D. P.; Zhang, X.; Sun, H.; Zhao, W.; Schimmer, A. D.; Turkson, J.; Gunning, P. T. Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein Bioorg. Med. Chem. 2011, 19, 1823-1838
23. Gunning, P. T.; Katt, W. P.; Glenn, M.; Siddique, K.; Kim, J. S.; Jove, R.; Sebti, S. M.; Turkson, J.; Hamilton, A. D. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: Structural recognition of STAT SH2 domains Bioorg. Med. Chem. Lett. 2007, 17, 1875-1878 (Pubitemid 46367686)
24. Hao, W.; Hu, Y.; Niu, C.; Huang, X.; Chang, C.-B.; Gibbons, J.; Xu, J. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening Bioorg. Med. Chem. Lett. 2008, 18, 4988-4992
25. Shahani, V. M.; Yue, P.; Haftchenary, S.; Zhao, W.; Lukkarila, J. L.; Zhang, X.; Ball, D.; Nona, C.; Gunning, P. T.; Turkson, J. Identification of purine-scaffold small-molecule inhibitors of stat3 activation by QSAR studies ACS Med. Chem. Lett. 2011, 2, 79-84
26. Fletcher, S.; Singh, J.; Zhang, X.; Yue, P.; Page, B. D. G.; Sharmeen, S.; Shahani, V. M.; Zhao, W.; Schimmer, A. D.; Turkson, J.; Gunning, P. T. Disruption of transcriptionally active stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: Potent in vitro and tumor cell activities ChemBioChem 2009, 10, 1959-1964
27. Page, B. D. G.; Fletcher, S.; Yue, P.; Li, Z.; Zhang, X.; Sharmeen, S.; Datti, A.; Wrana, J. L.; Trudel, S.; Schimmer, A. D.; Turkson, J.; Gunning, P. T. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain Bioorg. Med. Chem. Lett. 2011, 21, 5605-5609
28. Zhang, X.; Yue, P.; Fletcher, S.; Zhao, W.; Gunning, P. T.; Turkson, J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes Biochem. Pharmacol. 2010, 79, 1398-1409
29. Siddiquee, K.; Zhang, S.; Guida, W. C.; Blaskovich, M. A.; Greedy, B.; Lawrence, H. R.; Yip, M. L. R.; Jove, R.; McLaughlin, M. M.; Lawrence, N. J.; Sebti, S. M.; Turkson, J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 7391-7396 (Pubitemid 47185916)
30. Zhang, X.; Yue, P.; Fletcher, S.; Zhao, W.; Gunning, P. T.; Turkson, J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes Biochem. Pharmacol. 2010, 79, 1398-1409
31. Zhang, X.; Yue, P.; Page, B. D. G.; Li, T.; Zhao, W.; Namanja, A. T.; Paladino, D.; Zhao, J.; Chen, Y.; Gunning, P. T.; Turkson, J. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 9623-9628
32. Totrov, M.; Abagyan, R. Flexible protein-ligand docking by global energy optimization in internal coordinates Proteins: Struct., Funct., Genet. 1997, 29, 215-220 (Pubitemid 28090502)
33. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748 (Pubitemid 27170693)
34. Schust, J.; Berg, T. A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3 Anal. Biochem. 2004, 330, 114-118 (Pubitemid 38746981)
35. Greil, R.; Fasching, B.; Loidl, P.; Huber, H. Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: An in situ analysis Blood 1991, 78, 180-191